Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
NanoCarrier Ltd. logo — company profile

NanoCarrier Ltd.

Founded 1996 14 employees Post-IPO Debt Total: $8.28B Biotechnology, Pharmaceutical

General Information

Company Name NanoCarrier Ltd.
Founded Year 1996
Employees 14
Industries Biotechnology, Pharmaceutical
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with NanoCarrier Ltd.. To contact NanoCarrier Ltd., visit nanocarrier.co.jp.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NanoCarrier Ltd. compare?

A PDF of NanoCarrier Ltd. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NanoCarrier Ltd. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NanoCarrier Ltd.

NanoCarrier Ltd. is a biotechnology and pharmaceutical startup founded in 1996. The company's core technology, "micellar nanoparticles technology," originates from research conducted by Professor Kazunori Kataoka of the University of Tokyo and Professor Teruo Okano of Tokyo Women's Medical University. This technology has shown promising results in drug delivery, specifically in the treatment of cancer and other intractable diseases. NanoCarrier's flagship products in clinical development include NC-6004, a Cisplatin-based formulation designed to deliver the drug without its associated toxicities, and NC-4016, a DachPt micelle formulation with a similar function to Oxaliplatin. The company has received a significant ¥3.08BPost-IPO debt investment from Whiz Partners on 18 September 2015. With its focus on oncology, NanoCarrier aims to further improve the efficacy and safety of drugs through its micellar nanoparticles technology, potentially revolutionizing the medication of cancer and other challenging diseases.

Business keywords: micellar nanoparticles technology, drug delivery, oncology medication, nanoparticle-based therapies, drug development, cancer treatment, precision medicine, nanotechnology, medical research, drug safety, nanoparticle formulation, siRNA delivery, oncology drugs, clinical development, drug efficacy

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt ¥3.08B 1
Whiz Partners
Whiz Partners
18 Sep 2015
Post IPO Debt ¥1.71B 1
Whiz Partners
Whiz Partners
26 Jan 2012
Venture Round ¥1.36B 3
The University of Tokyo Edge Capital
The University of Tokyo Edge Capital, Teikoku Pharma +1
22 Mar 2007
Corporate Round ¥399.00M 3
Nippon Kayaku, Fulcrum Pharma Developments +1
20 Mar 2006
Venture Round ¥1.73B 1
Nomura Research and Advisory
Nomura Research and Advisory
31 Jan 2004

NanoCarrier Ltd. Alternatives & Competitors

View All Alternatives
NanoCarrier Ltd. vs
GLG Pharma
GLG Pharma United States

Why Show the GSK Compound? Because the cancer cells become resistant. How? By STAT3! GLG's Compounds...

Venture round
3 employees
Biotechnology, Health Care
NanoCarrier Ltd. vs
VRise Therapeutics, Inc.
VRise Therapeutics, Inc. United States

A Precision Oncology Company

5 employees
Biopharma, Biotechnology
NanoCarrier Ltd. vs
Cytimmune Sciences
Cytimmune Sciences United States

Developing safer more effective therapies that can attack tumors on multiple fronts simultaneously.

Venture round
6 employees
Biotechnology, Health Care
View all alternatives

FAQ About NanoCarrier Ltd.

NanoCarrier's core technology, "micellar nanoparticles technology", was proposed and has been researched by Professor Kazunori Kataoka of University of Tokyo, Professor Teruo Okano of Tokyo Women's Medical University. The aforementioned professors demonstrated that when drug-encapsulating micell...
NanoCarrier Ltd. was founded in 1996.
NanoCarrier Ltd. operates in Biotechnology and Pharmaceutical. Its work centres on micellar nanoparticles technology, drug delivery, oncology medication and nanoparticle-based therapies.
NanoCarrier Ltd. has approximately 14 employees.
NanoCarrier Ltd. has completed 5 funding rounds, raising a total of $8.28B. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to NanoCarrier Ltd. include GLG Pharma, VRise Therapeutics, Inc., Cytimmune Sciences, Prescient Therapeutics, Elevation Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NanoCarrier Ltd. and GLG Pharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NanoCarrier Ltd., https://bouncewatch.com/company/nanocarrier-ltd, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout